Global Glycogen Storage Disorders (GSD) Clinical Trials Market Size Set to Expand at CAGR of 12.02% During 2024–2030
Global Glycogen Storage Disorders (GSD) Clinical Trials Market is flourishing because of an increasing number of R&D programs aimed at treating glycogen storage disorders and growing awareness among stakeholders about rare illnesses.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, expects the Global Glycogen Storage Disorders (GSD) Clinical Trials Market size to expand at a significant CAGR of 12.02% during the forecast period between 2024 and 2030. Rapid adoption of technological advancements, increasing investments by government and private organizations in clinical trials for the development of treatment methods, and growing awareness among patient and medical professional about glycogen storage disorders are major growth factors for the Global Glycogen Storage Disorders (GSD) Clinical Trials Market. Furthermore, the discovery and approval of innovative therapeutics for GSDs are likely to present substantial growth opportunities to the players in the Global Glycogen Storage Disorders (GSD) Clinical Trials Market.
Opportunity – Increasing prevalence of glycogen storage disorders (GSD)
According to National Organization for Rare Disorders, glycogen storage disorder (GSD) is a rare disease, with Type I glycogen storage disorder being the most common type, which is estimated to occur in 1 case per 100,000 live births. The symptom of GSD begins at three to four months of age but may develop later in life. Furthermore, its symptom also overlaps with other chronic diseases, like low blood sugar (hypoglycemia) in diabetes, which may lead to incorrect diagnosis and treatment. As a result, the industry is undergoing extensive research and development activities for GSD clinical trials to understand its symptoms and develop treatment methods, which is anticipated to drive the global market during the forecast period.
Impact of Escalating Geopolitical Tensions on Global Glycogen Storage Disorders (GSD) Clinical Trials Market
The escalating geopolitical tensions affect the Global Glycogen Storage Disorders (GSD) Clinical Trials Market. For instance, Ukraine has been a leading medical research country, having completed a total of 1,177 clinical trials in the decade before Russia’s invasion in 2022, as reported on Pharmaceutical Technology. However, the Russia’s war completely disrupted the clinical trials sector in Ukraine, including the Glycogen Storage Disorders (GSD) Clinical Trials Market. More than half of the clinical trials conducted in Ukraine are internationally funded and commercially sponsored. However, with the shift of investments toward humanitarian causes as well as the lack of resources and supply chain disruptions in Ukraine’s medical research sector, the Global Glycogen Storage Disorders (GSD) Clinical Trials Market has suffered significant losses.
Global Glycogen Storage Disorders (GSD) Clinical Trials Market
Segmental Coverage
Global Glycogen Storage Disorders (GSD) Clinical Trials Market – By Type
Based on type, the Global Glycogen Storage Disorders (GSD) Clinical Trials Market is segmented into OTC and Rx drugs. The OTC drugs segment holds a larger share in the Global Glycogen Storage Disorders (GSD) Clinical Trials Market. Glycogen storage disorder has no known cure; hence, symptom management is the primary method of treatment, as the Cleveland Clinic states. The over the counter (OTC) segment offers medications to treat common symptoms of GSD, including low blood sugar, high cholesterol, and uric acid levels, all of which support the segment's expansion.
Global Glycogen Storage Disorders (GSD) Clinical Trials Market – By Region
The in-depth research report on the Global Glycogen Storage Disorders (GSD) Clinical Trials Market covers the market in a number of major countries across five regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa. North America dominates the Global Glycogen Storage Disorders (GSD) Clinical Trials Market. The United States ranks highest in the academic field of clinical medicine owing to the high concentration of pharmaceutical companies and renowned research institutions and therefore attracts significant investments in research and development activities in medical research.
Competitive Landscape
Major players operating in the Global Glycogen Storage Disorders (GSD) Clinical Trials Market include Merck, Sanofi, Nestlé Health Science, Mayo Clinical Laboratories, Reneo Pharmaceuticals, CHOC, Duke Health, and Ultragenyx.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Glycogen Storage Disorders (GSD) Clinical Trials Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Glycogen Storage Disorders (GSD) Clinical Trials Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
- 1. Research Framework
- 1.1. Research Objective
- 1.2. Type Overview
- 1.3. Market Segmentation
- 2. Executive Summary
- 3. Global Glycogen Storage Disorders (GSD) Clinical Trials Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Growing Awareness among Healthcare Professionals, Patients, and Advocacy Groups About Rare Diseases
- 3.2.1.2. Rising Number of Research and Development Activities for the Treatment of Glycogen Storage Disorders (GSD)
- 3.2.2. Restraints
- 3.2.2.1. High Development Costs
- 3.2.2.2. Limited Patient Pool
- 3.2.3. Opportunities
- 3.2.3.1. Development of Novel Therapies
- 3.2.3.2. Expanding Clinical Trials to Diverse Geographic Regions
- 3.2.4. Challenges
- 3.2.4.1. Lack of Awareness about ISOBUS Technology and equipment Manufacturers
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter’s Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
- 4. Global Glycogen Storage Disorders (GSD) Clinical Trials Market Overview
- 4.1. Market Size & Forecast, 2019–2030
- 4.1.1. By Value (USD Billion)
- 4.2. Market Share & Forecast
- 4.2.1. By Type
- 4.2.1.1. OTC
- 4.2.1.2. Rx Drugs
- 4.2.2. By Application
- 4.2.2.1. Hospital
- 4.2.2.2. Retail Pharmacy
- 4.2.3. By Region
- 4.2.3.1. North America
- 4.2.3.2. Europe
- 4.2.3.3. Asia Pacific (APAC)
- 4.2.3.4. Latin America (LATAM)
- 4.2.3.5. Middle East and Africa (MEA)
- 5. North America Glycogen Storage Disorders (GSD) Clinical Trials Market
- 5.1. Market Size & Forecast, 2019–2030
- 5.1.1. By Value (USD Billion)
- 5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By Application
- 5.2.3. By Country
- 5.2.3.1. United States
- 5.2.3.1.1. By Type
- 5.2.3.1.2. By Application
- 5.2.3.2. Canada
- 5.2.3.2.1. By Type
- 5.2.3.2.2. By Application
- 6. Europe Glycogen Storage Disorders (GSD) Clinical Trials Market
- 6.1. Market Size & Forecast, 2019–2030
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
- 6.2.3.1. Germany
- 6.2.3.1.1. By Type
- 6.2.3.1.2. By Application
- 6.2.3.2. United Kingdom
- 6.2.3.2.1. By Type
- 6.2.3.2.2. By Application
- 6.2.3.3. Italy
- 6.2.3.3.1. By Type
- 6.2.3.3.2. By Application
- 6.2.3.4. France
- 6.2.3.4.1. By Type
- 6.2.3.4.2. By Application
- 6.2.3.5. Spain
- 6.2.3.5.1. By Type
- 6.2.3.5.2. By Application
- 6.2.3.6. Belgium
- 6.2.3.6.1. By Type
- 6.2.3.6.2. By Application
- 6.2.3.7. Russia
- 6.2.3.7.1. By Type
- 6.2.3.7.2. By Application
- 6.2.3.7.3.
- 6.2.3.8. The Netherlands
- 6.2.3.8.1. By Type
- 6.2.3.8.2. By Application
- 6.2.3.9. Rest of Europe
- 6.2.3.9.1. By Type
- 6.2.3.9.2. By Application
- 7. Asia Pacific Glycogen Storage Disorders (GSD) Clinical Trials Market
- 7.1. Market Size & Forecast, 2019–2030
- 7.1.1. By Value (USD Billion)
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
- 7.2.3.1. China
- 7.2.3.1.1. By Type
- 7.2.3.1.2. By Application
- 7.2.3.2. India
- 7.2.3.2.1. By Type
- 7.2.3.2.2. By Application
- 7.2.3.3. Japan
- 7.2.3.3.1. By Type
- 7.2.3.3.2. By Application
- 7.2.3.4. South Korea
- 7.2.3.4.1. By Type
- 7.2.3.4.2. By Application
- 7.2.3.5. Australia & New Zealand
- 7.2.3.5.1. By Type
- 7.2.3.5.2. By Application
- 7.2.3.6. Indonesia
- 7.2.3.6.1. By Type
- 7.2.3.6.2. By Application
- 7.2.3.7. Malaysia
- 7.2.3.7.1. By Type
- 7.2.3.7.2. By Application
- 7.2.3.8. Singapore
- 7.2.3.8.1. By Type
- 7.2.3.8.2. By Application
- 7.2.3.9. Vietnam
- 7.2.3.9.1. By Type
- 7.2.3.9.2. By Application
- 7.2.3.10. Rest of APAC
- 7.2.3.10.1. By Type
- 7.2.3.10.2. By Application
- 8. Latin America Glycogen Storage Disorders (GSD) Clinical Trials Market
- 8.1. Market Size & Forecast, 2019–2030
- 8.1.1. By Value (USD Billion)
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
- 8.2.3.1. Brazil
- 8.2.3.1.1. By Type
- 8.2.3.1.2. By Application
- 8.2.3.2. Mexico
- 8.2.3.2.1. By Type
- 8.2.3.2.2. By Application
- 8.2.3.3. Argentina
- 8.2.3.3.1. By Type
- 8.2.3.3.2. By Application
- 8.2.3.4. Peru
- 8.2.3.4.1. By Type
- 8.2.3.4.2. By Application
- 8.2.3.5. Rest of LATAM
- 8.2.3.5.1. By Type
- 8.2.3.5.2. By Application
- 9. Middle East and Africa Glycogen Storage Disorders (GSD) Clinical Trials Market
- 9.1. Market Size & Forecast, 2019–2030
- 9.1.1. By Value (USD Billion)
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
- 9.2.3.1. Saudi Arabia
- 9.2.3.1.1. By Type
- 9.2.3.1.2. By Application
- 9.2.3.2. UAE
- 9.2.3.2.1. By Type
- 9.2.3.2.2. By Application
- 9.2.3.3. Qatar
- 9.2.3.3.1. By Type
- 9.2.3.3.2. By Application
- 9.2.3.4. Kuwait
- 9.2.3.4.1. By Type
- 9.2.3.4.2. By Application
- 9.2.3.5. South Africa
- 9.2.3.5.1. By Type
- 9.2.3.5.2. By Application
- 9.2.3.6. Nigeria
- 9.2.3.6.1. By Type
- 9.2.3.6.2. By Application
- 9.2.3.7. Algeria
- 9.2.3.7.1. By Type
- 9.2.3.7.2. By Application
- 9.2.3.8. Rest of MEA
- 9.2.3.8.1. By Type
- 9.2.3.8.2. By Application
- 10. Competitive Landscape
- 10.1. List of Key Players and Their Offerings
- 10.2. Global Glycogen Storage Disorders (GSD) Clinical Trials Company Market Share Analysis, 2023
- 10.3. Competitive Benchmarking, By Operating Parameters
- 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
- 11. Impact of Escalating Geopolitical Tensions on Global Glycogen Storage Disorders (GSD) Clinical Trials Market
- 12. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
- 12.1. Merck
- 12.2. Sanofi
- 12.3. Nestlé Health Science
- 12.4. Mayo clinical laboratories
- 12.5. Reneo Pharmaceuticals
- 12.6. CHOC
- 12.7. Duke health
- 12.8. Ultragenyx
- 12.9. Other Prominent Players
- 13. Key Strategic Recommendations
- 14. Research Methodology
- 14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
- 14.2. Quantitative Research
- 14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research˙
- 14.3.2. Primary Research
- 14.4. Breakdown of Primary Research Respondents, By Region
- 14.5. Assumptions & Limitations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook